EFPIA's 'Integrated Strategy' in Europe: Out of the Frying Pan, Into the Fire? - Pharmaceutical Executive

ADVERTISEMENT

EFPIA's 'Integrated Strategy' in Europe: Out of the Frying Pan, Into the Fire?


Pharmaceutical Executive


It's difficult to open an email or an envelope in Brussels these days without yet another agenda falling out of it, carrying the promise of a new start. With a new European Parliament installed, a new European Commission president appointed and a new Commission on the way, and guarded optimism that the worst of the recession is over, this outpouring of recommendations and recipes is hardly surprising. Hope springs eternal in the human breast.

The trend is reflected in the medicines sector, with a plethora of manifestos and strategy proposals from industry, regulators, and campaigning organizations. One of the most grandiose is the self-styled "groundbreaking vision towards a life sciences strategy for Europe," launched in high summer by the European Federation of Pharmaceutical Industries and Associations.

This "landmark paper" claims to provide steps towards "an integrated strategy" for the sector in Europe. "With Europe now emerging from the crisis, there is an opportunity to improve health prospects of citizens, while promoting economic growth. As new European leaders and policymakers across the political spectrum begin work to improve Europe's future, EFPIA calls for greater political collaboration," the industry association specifies.

Into the fire

It is reasonable to expect that new European leaders and policymakers will begin work to improve Europe's future. But given the notorious absence of political collaboration in European health affairs, it is imprudent to assume that all that work will improve the situation for the drug industry. Given the fundamental nature of the challenges that Europe is facing, what emerges may actually be worse than the current imperfect context for medicines. EFPIA and other industry advocates of radical change run the risk of jumping out of the frying pan only to find themselves in the fire.




The essence of the EFPIA call to arms is a plea for "a new generation of partnerships and collaborative solutions to address the EU's growing health and competitiveness challenges." It urges changes in perception, more "thinking outside the box," better understanding of future demands and of the value of investment, and the "need to address the system as a whole" in order to create sustainable systems. Of course the central refrain of the vision is "ensuring that the pharmaceutical and life sciences industries—jewels in Europe's economy—continue to thrive." Consequently, much of the content is devoted to the need for the industry to be "highly competitive" and for "innovation-led growth." The merits of the industry—in terms of those familiar claims relating to products, jobs, exports, or research commitment—occupy much of this manifesto.

So, too, does the catalogue of the economic problems the industry faces. EFPIA warns against "making it difficult to obtain innovative medicines, increasing user charges, or delisting services from the benefits catalogue." It complains about the distortion that international reference pricing creates in the European market for medicines—going so far as to call for an urgent review of "the practical operation of the free movement of goods principle in medicines." It blames "the current patchwork of valuation and assessment criteria across Europe" for being "arbitrary and politicized," and "leading to wasteful and costly duplication of effort." And it cautions that "arbitrary financial policies" are inhibiting investment in research.


ADVERTISEMENT

blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here